Related Experiment Videos

[Perimembranous glomerulonephritis after treatment with D-penicillamine. Report on 31 cases (author's transl)]

Klinische Wochenschrift
|September 1, 1975
PubMed

Insights

D-Penicillamine treatment can cause perimembranous glomerulonephritis, leading to proteinuria and nephrotic syndrome in patients. Kidney function may improve after discontinuing D-Penicillamine therapy.

Area of Science:

  • Nephrology
  • Pharmacology
  • Pathology

Background:

  • D-Penicillamine is a chelating agent used to treat various conditions.
  • Drug-induced nephropathies are a significant concern in clinical practice.

Observation:

  • Thirty-one patients developed perimembranous glomerulonephritis (MPGN) after D-Penicillamine treatment.
  • Common symptoms included proteinuria and, in some cases, hematuria.
  • Nephrotic syndrome developed in 20 patients after treatment cessation.

Findings:

  • MPGN onset typically occurred around 7 months into D-Penicillamine therapy.
  • Proteinuria was a consistent finding, with hematuria present in 12 patients.
  • Five patients showed reduced MPGN on repeat biopsy after treatment withdrawal, indicating potential reversibility.

Implications:

  • Discontinuation of D-Penicillamine may lead to recovery from drug-induced MPGN.
  • Monitoring for renal complications is crucial in patients receiving D-Penicillamine.
  • Understanding the pathogenesis of D-Penicillamine-induced nephropathy can inform treatment strategies.

Related Concept Videos